Breast Cancer – Landscape & Forecast – Disease Landscape & Forecast
The treatment of breast cancer is associated with strong commercial opportunity because of the disease’s high incidence, long treatment durations, and multiple lines of therapy. The CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio/Verzenios) are entrenched in the treatment of HR-positive / HER2-negative disease, a trend that will continue through 2032. Current treatment options for HER2-positive breast cancer have expanded, owing to the launch of novel HER2-targeting agents (Daiichi Sankyo / AstraZeneca’s Enhertu, Seagen / Pfizer’s Tukysa, and MacroGenics’ Margenza), sales of which will offset the entry of generics and biosimilars. In triple-negative breast cancer, the approvals of PARP inhibitors (AstraZeneca / Merck & Co.’s Lynparza, Pfizer’s Talzenna), immune checkpoint inhibitors (Merck & Co.’s Keytruda), and TROP2-targeted agents (Gilead’s Trodelvy) are diversifying therapy options for patients. Enhertu’s approval in 2022 for HER2-low disease, a new subset of breast cancer, will further reshape the treatment landscape.
QUESTIONS ANSWERED
- What is the size of clinically and commercially relevant drug-treatable breast cancer populations, and how will drug-treatment rates change over time?
- What is the expected market impact of recent drug approvals, such as Trodelvy, Keytruda, Piqray, Enhertu, and Orserdu, on the various subpopulations of breast cancer?
- Which are the most promising agents in the pipeline, and how will they shape the future of the breast cancer therapy market?
- Which key drivers and constraints will affect the breast cancer therapy market over the forecast period?
CONTENT HIGHLIGHTS
- Geographies: United States, EU5, Japan.
- Primary research: 18 country-specific interviews with thought-leading medical oncologists supported by survey data collected for this and other Clarivate research.
- Epidemiology: Incidence of breast cancer by country, segmented by HR and HER2 status, staging, and line of therapy.
- Forecast: 10-year, annualized, drug-level sales and patient share of key breast cancer therapies through 2032, segmented by brands / biosimilars / generics and market-relevant drug-treatable populations.
- Emerging therapies: Phase 3/PR: 20 drugs; coverage of select Phase 1 and 2 products.
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Breast Cancer - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Key Updates
- Market Outlook
- Key findings
- Market share of breast cancer drug classes: 2022
- Market share of breast cancer drug classes: 2032
- Drug-treatable population share and major-market sales share in breast cancer: 2022
- Drug-treatable population share and major-market sales share in breast cancer: 2032
- Population positioning of current therapies in breast cancer
- Population positioning of emerging therapies in breast cancer
- SWOT analysis
- Market drivers and constraints
- Segment-specific trends
- Key findings
- Forecast
- Etiology and Pathophysiology
- Epidemiology
- Current Treatment
- Key findings
- Treatment goals
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for breast cancer
- Current treatments used for breast cancer
- Market events impacting the use of key current therapies for breast cancer
- HER2-targeted agents
- CDK4/6 inhibitors
- PI3K / AKT / mTOR pathway inhibitors
- Angiogenesis inhibitors
- Cytotoxic agents
- SERDs
- PARP inhibitors
- Immune checkpoint inhibitors
- PI3K inhibitors
- TROP2-targeted agents
- Medical practice
- Neoadjuvant treatment of stage II/III breast cancer
- Adjuvant treatment of stage I-III breast cancer
- First-line treatment of advanced / metastatic breast cancer
- Second- and subsequent-line treatment of advanced / metastatic breast cancer
- Patient characteristics influencing drug selection in breast cancer
- Region-specific treatment practices
- Key findings
- Unmet Need Overview
- Drug Pipeline
- Emerging Therapies
- Key findings
- Key emerging therapies
- Key therapies in development for breast cancer
- Estimated market authorization dates of key emerging therapies for breast cancer
- PI3K / AKT / mTOR pathway inhibitors
- Immune checkpoint inhibitors
- HER2-targeted agents
- CDK4/6 inhibitors
- Cytotoxic agents
- Cancer vaccines
- SERMs
- SERDs
- CERANs
- SARMs
- TROP2-targeted agents
- ER PROTAC degraders
- Early-phase pipeline analysis
- Key findings
- Access and Reimbursement Overview
- Methodology
- Appendix
Laura Ramos Garcia, M.Sc., Ph.D., is an analyst on the Oncology team at Clarivate. During her training as a Ph.D., she gained in-depth knowledge in the field of cell death and inflammation. As a postdoctoral researcher, she worked on an emerging type of small molecule, PROTAC, that allows targeted protein degradation. She obtained her master of science degree in molecular medicine at Imperial College London and her doctorate in cancer biology at the Institute of Cancer Research (University of London).
Harinder Kumar, B.D.S., M.P.H., is an associate epidemiologist at Clarivate. His areas of interest are cancer and psychiatric epidemiology. Previously, Dr. Kumar worked with the government of Punjab, National Health Mission, India. He received his M.P.H. from the Tata Institute of Social Sciences in Mumbai. He holds a B.D.S. in dentistry from the National Dental College and Hospital in Punjab.